Is AMGN Overvalued? DCF Says Worth $204

gurufocus.com · 2026-10-26

On October 26, 2026, we conducted a DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance recently, with a year-to-date increase

TickrTrends take: A discounted cash flow analysis suggests AMGN has an intrinsic value of $204, which aligns with TickrTrends' current overvalued assessment of the stock. Valuation-focused readers should monitor whether the stock price converges toward this DCF-derived level or whether management actions and earnings revisions shift the fundamental value estimate. Given AMGN's position in the Healthcare sector, tracking the company's pipeline progress and cash generation relative to this valuation benchmark will be important for understanding whether the overvaluation is temporary or persistent.

Read the full story at gurufocus.com →